2024
Cost-Effectiveness of Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder
Lu T, Ryan D, Cadet T, Chawarski M, Coupet E, Edelman E, Hawk K, Huntley K, Jalali A, O'Connor P, Owens P, Martel S, Fiellin D, D'Onofrio G, Murphy S. Cost-Effectiveness of Implementation Facilitation to Promote Emergency Department-Initiated Buprenorphine for Opioid Use Disorder. Annals Of Emergency Medicine 2024, 85: 205-213. PMID: 39570250, PMCID: PMC11845297, DOI: 10.1016/j.annemergmed.2024.10.001.Peer-Reviewed Original ResearchHealth care sector perspectiveImplementation facilitatorsOpioid use disorder careIncremental cost-effectiveness ratioCost-effectiveness ratioHealth care sector costsEducational strategiesImplementation facilitation strategyCost-effectiveness acceptability curvesLikelihood of cost-effectivenessCost-effectiveOpioid use disorderQuality-adjusted life yearsUse disorderPatient engagementAcademic EDED visitsAcceptability curvesStandard educationEmergency departmentLife yearsFacilitation strategiesMeasures of effectivenessHealthBuprenorphine
2023
Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics
Jawa R, Tin Y, Nall S, Calcaterra S, Savinkina A, Marks L, Kimmel S, Linas B, Barocas J. Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics. JAMA Network Open 2023, 6: e237888. PMID: 37043198, PMCID: PMC10098970, DOI: 10.1001/jamanetworkopen.2023.7888.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioPrimary care practitionersClinical outcomesPCP servicesPrimary careAddiction servicesAddiction careUS primary care clinicsLong-term clinical outcomesHealth care sector costsInjection-related infectionsPrimary care clinicsHealth care sector perspectivePrimary care practicesCost-effectiveness ratioObservational cohortBuprenorphine prescribingCare clinicsClinical trialsPCP practicesTreatment strategiesMAIN OUTCOMESimulated cohortCare practitionersCare practicesCost‐Effectiveness of Weight‐Loss Interventions Prior to Total Knee Replacement for Patients With Class III Obesity
Kostic AM, Leifer VP, Selzer F, Hunter DJ, Paltiel AD, Chen AF, Robinson MK, Neogi T, Collins JE, Messier SP, Edwards RR, Katz JN, Losina E. Cost‐Effectiveness of Weight‐Loss Interventions Prior to Total Knee Replacement for Patients With Class III Obesity. Arthritis Care & Research 2023, 75: 1752-1763. PMID: 36250415, PMCID: PMC10375659, DOI: 10.1002/acr.25044.Peer-Reviewed Original ResearchConceptsLaparoscopic sleeve gastrectomyClass III obesityIncremental cost-effectiveness ratioTotal knee replacementQuality-adjusted life expectancyWeight loss interventionProbabilistic sensitivity analysesKnee replacementNonsurgical weight loss interventionsLong-term clinical benefitWeight lossKnee osteoarthritis patientsWeight loss strategiesHealth care sector perspectiveOsteoarthritis Policy ModelLifetime medical costsCost-effectiveness ratioWeight loss/Gastric bypassSleeve gastrectomyPrimary outcomeLoss interventionOsteoarthritis patientsClinical benefitHigher complications
2022
Cost‐Effectiveness of Surgical Weight‐Loss Interventions for Patients With Knee Osteoarthritis and Class III Obesity
Kostic A, Leifer V, Gong Y, Robinson M, Collins J, Neogi T, Messier S, Hunter D, Selzer F, Suter L, Katz J, Losina E. Cost‐Effectiveness of Surgical Weight‐Loss Interventions for Patients With Knee Osteoarthritis and Class III Obesity. Arthritis Care & Research 2022, 75: 491-500. PMID: 35657632, PMCID: PMC9827536, DOI: 10.1002/acr.24967.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioLaparoscopic sleeve gastrectomyClass III obesityUsual careLifetime costsHealth care sector perspectiveProbabilistic sensitivity analysesCost-effectiveness ratioQuality-adjusted life expectancyOsteoarthritis Policy ModelSurgical weight loss interventionsLong-term clinical benefitKnee OA patientsKnee osteoarthritis patientsSensitivity analysisSustainable weight lossWeight loss interventionWorse knee painKnee replacement outcomesPolicy modelSector perspectiveTotal knee replacement outcomesGastric bypassKnee painOpioid usePopulation‐level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost‐effectiveness analysis
Savinkina A, Madushani RWMA, Yazdi G, Wang J, Barocas JA, Morgan JR, Assoumou SA, Walley AY, Linas BP, Murphy SM. Population‐level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost‐effectiveness analysis. Addiction 2022, 117: 2450-2461. PMID: 35315162, PMCID: PMC9377514, DOI: 10.1111/add.15879.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioOpioid use disorderStandard of careUse disordersFatal overdosesDetox patientsMOUD initiationWithdrawal programInitiation of medicationHealth care sector perspectiveRisk of overdoseFatal opioid overdosesCost-effectiveness ratioCost-effectiveness analysisOpioid useHealth care spendingOutpatient careDetox programsOpioid overdosesMOUDPatientsOverdosesPopulation-level impactDisorder populationHealth effects
2021
Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
Yang SC, Kunst N, Gross CP, Wang JD, Su WC, Wang SY. Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer. Frontiers In Oncology 2021, 11: 760686. PMID: 34956882, PMCID: PMC8695441, DOI: 10.3389/fonc.2021.760686.Peer-Reviewed Original ResearchNon-small cell lung cancerIncremental cost-effectiveness ratioMetastatic non-small cell lung cancerCell lung cancerHealth care sector perspectivePD-L1Lung cancerAdvanced non-small cell lung cancerPD-L1 expression levelsCycles of chemotherapyProgression-free survivalFirst-line treatmentCost-effectiveness ratioExpression levelsCheckMate 227Overall survivalSubgroup analysisLifetime horizonOutcome dataChemotherapyPatientsIpilimumabNivolumabQALYSector perspective
2020
Thermal ablation versus stereotactic body radiotherapy for stage I non-small cell lung cancer: A cost-effectiveness analysis.
Wu X, Uhlig J, Blasberg J, Gettinger S, Suh R, Solomon S, Kim K. Thermal ablation versus stereotactic body radiotherapy for stage I non-small cell lung cancer: A cost-effectiveness analysis. Journal Of Clinical Oncology 2020, 38: e21061-e21061. DOI: 10.1200/jco.2020.38.15_suppl.e21061.Peer-Reviewed Original ResearchNon-small cell lung cancerStereotactic body radiotherapyIncremental cost-effectiveness ratioStage I non-small cell lung cancerOne-way sensitivity analysesCell lung cancerBody radiotherapyRecurrence riskLung cancerHealth benefitsStage I NSCLC patientsLong-term prospective trialsPerfect healthAnnual recurrence riskHealth care sector perspectiveShort-term complicationsSensitivity analysisLong-term surveillanceThermal ablationWeeks of lifeCost-effectiveness analysisCost-effectiveness ratioDeterministic sensitivity analysesMedicare billing dataMultiple sensitivity analyses
2019
Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis
Losina E, Smith KC, Paltiel AD, Collins JE, Suter LG, Hunter DJ, Katz JN, Messier SP. Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis. Arthritis Care & Research 2019, 71: 855-864. PMID: 30055077, PMCID: PMC6349519, DOI: 10.1002/acr.23716.Peer-Reviewed Original ResearchMeSH KeywordsAgedCaloric RestrictionComparative Effectiveness ResearchComputer SimulationCost-Benefit AnalysisExerciseFemaleHealth Care CostsHealthy LifestyleHumansMaleMiddle AgedModels, EconomicMonte Carlo MethodObesityOsteoarthritis, KneeQuality of LifeQuality-Adjusted Life YearsRisk Reduction BehaviorTime FactorsTreatment OutcomeWeight LossConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesKnee osteoarthritisObese patientsIntensive dietSocietal perspectiveHealth care sector perspectiveLifetime costsOsteoarthritis Policy ModelCost-effectiveness ratioIDEA trialPain reductionUsual careExercise programArthritis trialsTreatment strategiesLifetime horizonClinical practicePatientsOsteoarthritisOverweightQALYHealth care sectorWeight reductionDietCost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events
Sehested T, Bjerre J, Ku S, Chang A, Jahansouz A, Owens D, Hlatky M, Goldhaber-Fiebert J. Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events. JAMA Cardiology 2019, 4: 128-135. PMID: 30649147, PMCID: PMC6439626, DOI: 10.1001/jamacardio.2018.4566.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCost-effectiveness ratioIncremental cost-effectiveness ratioRecurrent cardiovascular eventsHealth-related quality of lifeStandard of careCanakinumab Anti-inflammatory Thrombosis Outcomes StudyHs-CRP levelsLung cancer incidenceHealth-related qualityMyocardial infarctionCardiovascular eventsRate of recurrent MIHealth care sector perspectiveReduced all-cause mortalityQuality of lifeAll-Cause MortalityCost-effectiveUS health care sector perspectiveHs-CRPCancer incidenceRisk of recurrent cardiovascular eventsMain OutcomesHigh-sensitivity C-reactive proteinSubstantial price reductions
2018
Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial.
Yoon J, Zisook S, Park A, Johnson GR, Scrymgeour A, Mohamed S. Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2018, 80 PMID: 30695291, DOI: 10.4088/jcp.18m12294.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive Agents, Second-GenerationAripiprazoleBupropionCost-Benefit AnalysisDepressionDepressive Disorder, MajorDrug SubstitutionDrug SynergismDrug Therapy, CombinationFemaleHumansMaleMiddle AgedOutcome Assessment, Health CareRemission InductionUnited StatesUnited States Department of Veterans AffairsVeteransConceptsIncremental cost-effectiveness ratioStandard antidepressant therapyBupropion augmentationAripiprazole augmentationAntidepressant therapyClinical trialsVeterans Affairs Medical CenterDepression Outcomes trialMental health care costsRate of remissionRandomized clinical trialsHealth care sector perspectiveICD-9 codesTreatment of depressionCost-effectiveness ratioHealth care costsCost-effective relativeCost-effectiveness analysisOutcome trialsMean ageQuick InventoryDepression diagnosisTreatment strategiesRemissionMedical Center
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply